ADMA Biologics affirms 2024-2025 guidance unaffected by auditor switch

ADMA BIOLOGICS, INC.

Management stated no anticipated impact to previously provided 2024-2025 financial guidance from auditor transition.
Statement made after market close on Oct 9, 2024, in discussions with analysts.
Auditor change described in separate Form 8-K filed on Oct 9, 2024.

item 7.01 item 9.01

ADMA BIOLOGICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-24-043250

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.